Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications
- PMID: 36430344
- PMCID: PMC9692470
- DOI: 10.3390/ijms232213869
Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications
Abstract
Bladder cancer is the 10th most common cancer worldwide. Due to the lack of understanding of the oncogenic mechanisms between muscle-invasive bladder cancer (MIBC) and advanced bladder cancer (ABC) and the limitations of current treatments, novel therapeutic approaches are urgently needed. In this study, we utilized the systems biology method via genome-wide microarray data to explore the oncogenic mechanisms of MIBC and ABC to identify their respective drug targets for systems drug discovery. First, we constructed the candidate genome-wide genetic and epigenetic networks (GWGEN) through big data mining. Second, we applied the system identification and system order detection method to delete false positives in candidate GWGENs to obtain the real GWGENs of MIBC and ABC from their genome-wide microarray data. Third, we extracted the core GWGENs from the real GWGENs by selecting the significant proteins, genes and epigenetics via the principal network projection (PNP) method. Finally, we obtained the core signaling pathways from the corresponding core GWGEN through the annotations of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to investigate the carcinogenic mechanisms of MIBC and ABC. Based on the carcinogenic mechanisms, we selected the significant drug targets NFKB1, LEF1 and MYC for MIBC, and LEF1, MYC, NOTCH1 and FOXO1 for ABC. To design molecular drug combinations for MIBC and ABC, we employed a deep neural network (DNN)-based drug-target interaction (DTI) model with drug specifications. The DNN-based DTI model was trained by drug-target interaction databases to predict the candidate drugs for MIBC and ABC, respectively. Subsequently, the drug design specifications based on regulation ability, sensitivity and toxicity were employed as filter criteria for screening the potential drug combinations of Embelin and Obatoclax for MIBC, and Obatoclax, Entinostat and Imiquimod for ABC from their candidate drugs. In conclusion, we not only investigated the oncogenic mechanisms of MIBC and ABC, but also provided promising therapeutic options for MIBC and ABC, respectively.
Keywords: advanced bladder cancer (ABC); deep neural network (DNN)-based drug-target interaction (DTI) model; drug combination; drug design specifications; drug targets; muscle-invasive bladder cancer (MIBC).
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.Int J Mol Sci. 2022 Sep 8;23(18):10409. doi: 10.3390/ijms231810409. Int J Mol Sci. 2022. PMID: 36142321 Free PMC article.
-
Drug Target Identification and Drug Repurposing in Psoriasis through Systems Biology Approach, DNN-Based DTI Model and Genome-Wide Microarray Data.Int J Mol Sci. 2023 Jun 12;24(12):10033. doi: 10.3390/ijms241210033. Int J Mol Sci. 2023. PMID: 37373186 Free PMC article.
-
Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.Int J Mol Sci. 2022 Mar 26;23(7):3649. doi: 10.3390/ijms23073649. Int J Mol Sci. 2022. PMID: 35409008 Free PMC article.
-
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Urol Oncol. 2016. PMID: 27317490 Review.
-
New horizons in bladder cancer research.Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7. Urol Oncol. 2020. PMID: 30852032 Review.
Cited by
-
The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Brief Bioinform. 2024 Jan 22;25(2):bbad527. doi: 10.1093/bib/bbad527. Brief Bioinform. 2024. PMID: 38279645
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous